NCT02343536 - A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 29, 2015

Primary Completion Date

January 29, 2020

Study Completion Date

January 29, 2020

Conditions

Lymphoma, Large B-Cell, DiffuseLymphoma, Follicular

Interventions

DRUG

Oral Azacitidine

DRUG

Rituximab

DRUG

cyclophosphamide

DRUG

Vincristine

DRUG

Prednisone

Trial Locations (7)

Weill Cornell Medicine, New York

Moffitt Cancer Center, Tampa

University of Chicago, Chicago

Washington University School of Medicine, St Louis

Massachusetts General Hospital, Boston

Dana Farber Cancer Institute, Boston

Rhode Island Hospital, Providence